10538-65-5
10538-65-5 結(jié)構(gòu)式
基本信息
甲基-7-氧代-3A,12A-二羥基-5B-膽酸酯
(3Α,5Β,12Α)-3,12-二羥基-7-酮基膽烷-24-酸甲酯
(3ALPHA,5BETA,12ALPHA)-3,12-二羥基-7-酮基膽烷-24-酸甲酯
Methyl-7-keto-3a,12a-dihydroxy-5b-cholanoate
3α,12α-diol-7-oxo-5β-24-cholanoic acid methyl ester, methyl
3α,12α-diol-7-oxo-5β-24-cholanoic acid Methyl ester, Methyl
(3a,5b,12a)-3,12-Dihydroxy-7-oxocholan-24-oic acid methyl ester
(3α,5β,12α)-3,12-Dihydroxy-7-oxocholan-24-oic acid Methyl ester
(3α,5β,12α)-3,12-Dihydroxy-7-oxocholan-24-oic acid methyl ester
Cholan-24-oic acid, 3,12-dihydroxy-7-oxo-, methyl ester, (3α,5β,12α)-
(3alpha,5beta,12alpha)-3,12-Dihydroxy-7-oxocholan-24-oic acid methyl ester
methyl (R)-4-((3R,5S,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-7-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate
制備方法
1448-36-8
15073-97-9
以(R)-甲基 4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-三羥基-10,13-二甲基十六氫-1H-環(huán)戊[a]菲蒽17-基)戊酸酯為起始原料，首先通過保護(hù)膽酸羥基得到甲基酯（2）。隨后，使用N-溴代琥珀酰亞胺（NBS）將甲基酯（2）氧化為相應(yīng)的酮（3）。接著，將酮（3）作為二乙酸酯（4）進(jìn)行保護(hù)，并通過與分子溴反應(yīng)轉(zhuǎn)化為關(guān)鍵中間體溴化物（5）。之后，將溴化物（5）水解生成羥基酮（6）。最后，通過還原乙酸酯和甲酯部分，并進(jìn)行全面脫保護(hù)，得到目標(biāo)產(chǎn)物(R)-4-((3R,5S,8R,9S,10S,12S,13R,14S,17R)-3,12-二羥基-10,13-二甲基-7-氧代十六氫-1H-環(huán)戊并[a]菲-17-基)戊酸甲酯（7）。
參考文獻(xiàn)：
[1] Advanced Synthesis and Catalysis, 2012, vol. 354, # 14-15, p. 2821 - 2828
[2] Journal of the Chemical Society, Chemical Communications, 1993, # 19, p. 1469 - 1471
[3] Patent: WO2011/22838, 2011, A1. Location in patent: Page/Page column 37
[4] Journal of Biological Chemistry, 1943, vol. 147, p. 131,133
[5] Steroids, 1993, vol. 58, # 2, p. 52 - 58